Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Merck : Keytruda in Combination Reduced Risk of Death in Certain Esophageal Cancer Patients

share with twitter share with LinkedIn share with facebook
09/21/2020 | 01:24pm EDT

By Stephen Nakrosis

Merck & Co. Inc. on Monday said data from a Phase 3 trial of Keytruda in combination with platinum-based chemotherapy showed the treatment led to a reduced risk of death in certain esophageal cancer patients.

The company said its KEYNOTE-590 trial was evaluating Keytruda in combination with platinum-based chemotherapy as a "first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction cancer."

According to Merck, "Keytruda plus chemotherapy demonstrated superior overall survival and progression-free survival versus chemotherapy in these patients regardless of PD-l1 expression status and tumor histology." Merck also said, "Keytruda in combination with chemotherapy significantly improved overall survival, reducing the risk of death by 27% versus chemotherapy in all randomized patients."

The data were presented at the European Society for Medical Oncology Virtual Congress 2020 on Sept. 21, Merck said.

Merck added that it will be sharing the data with regulatory authorities worldwide.


--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. -0.63% 79.33 Delayed Quote.-12.23%
THE PLATINUM GROUP PUBLIC COMPANY LIMITED -1.92% 2.04 End-of-day quote.-50.00%
share with twitter share with LinkedIn share with facebook
All news about MERCK & CO., INC.
10/16MERCK : Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combi..
10/16MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA in Adult Patients ..
10/15MERCK : Issues 2019, 2020 Corporate Responsibility Report
10/15MERCK : Gets FDA Expanded Approval for Keytruda in Classical Hodgkin Lymphoma
10/15MERCK : Health Canada Approves KEYTRUDA® (pembrolizumab) as First-line Treatment..
10/15MERCK : FDA Approves Expanded Indication for Merck's KEYTRUDA® (pembrolizumab) i..
10/14MERCK : Announces Plans to Construct New Facility in the United States to Expand..
10/14MERCK : Issues 2019/2020 Corporate Responsibility Report
10/09MERCK : Intec Pharma Announces New Research Collaboration Agreement with MSD
10/09MODERNA : Announces Updates on Respiratory Syncytial Virus Vaccine Program
More news
Financials (USD)
Sales 2020 48 008 M - -
Net income 2020 11 997 M - -
Net Debt 2020 16 009 M - -
P/E ratio 2020 16,8x
Yield 2020 3,03%
Capitalization 202 B 202 B -
EV / Sales 2020 4,54x
EV / Sales 2021 4,20x
Nbr of Employees 71 000
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 20
Average target price 96,00 $
Last Close Price 79,83 $
Spread / Highest target 34,0%
Spread / Average Target 20,3%
Spread / Lowest Target 5,22%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-12.23%201 909
JOHNSON & JOHNSON1.53%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-6.71%210 884
NOVARTIS AG-14.09%190 074
NOVO NORDISK A/S16.93%165 474